These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32804915)

  • 1. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
    Li S; Ding J; Wang Y; Wang X; Lv L
    J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
    Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
    Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
    Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
    Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 11. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma.
    Guo Y; Yang X; Xia WL; Zhu WB; Li FT; Hu HT; Li HL
    BMC Cancer; 2024 Sep; 24(1):1120. PubMed ID: 39251968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
    Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1
    Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
    Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
    Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
    Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
    Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
    Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.